SEC For	rm 4 FORM	1		η στα		ECHE	лтп	ES AN		хсн	ΔΝΟ		омм	ISSION				
	FURIN	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					ed pursuar	NT OF CHANGES IN BENEFICIAL OWNE I pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									Estim	OMB Number: 323 Estimated average burden hours per response:		3235-0287 en 0.5
1. Name and Address of Reporting Person [*] Hallal David					<u>iTeo</u>	2. Issuer Name and Ticker or Trading Symbol <u>iTeos Therapeutics, Inc.</u> [ITOS] 3. Date of Earliest Transaction (Month/Day/Year)								S. Relationship of Reporting Person(s) to Issuer Check all applicable) X Director Officer (give title Other (specify				wner
(Last) (First) (Middle) C/O ITEOS THERAPEUTICS, INC.					06/13	06/13/2023								below) below)				
321 ARSENAL STREET					4. If An	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting			
(Street) WATERTOWN MA 02472					Dulo	Person												
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I - Noi	n-Deriv	ative S	ecuritie	s Ac	quired,	Dis	posed	of, c	or Ben	eficial	ly Owned	t			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,			Transaction Dispose Code (Instr. 5)			rities Acquired (A) or ed Of (D) (Instr. 3, 4 a		Benefici Owned	es ally Following	Form (D) o	vnership n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									v	Amou	Amount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
		г						juired, E s, optior						v Owned				
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date or Exercise (Month/Day/Year) if any		Date,	4. Transactic Code (Inst 8)	n of r. Deriva Securi Acquir (A) or Dispos of (D)	of E Derivative (Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy J	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi t (Instr. 4)	
				Г									Amount]				

(D) Date Exercisable

06/13/2024

Expiration Date

06/13/2033

Title

in-Fact

Common Stock or Number

of Shares

22,383

/s/ Adi Osovsky, as Attorney-

** Signature of Reporting Person

\$0.00

22,383

06/15/2023

Date

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/13/2023

Stock Option (Right to Buy)

Remarks:

\$14.77

Explanation of Responses:

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

v

(A)

22,383

Code

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.